Laduviglusib (dihydrochloride)
Laduviglusib; CHIR 99021; CHIR99021; CHIR-99021; CT99021; CT 99021; CT-99021
Product Specifications
CAS Number
2109414-84-6
Product Name Alternative
CHIR-99021 (dihydrochloride) ; CT99021 (dihydrochloride)
UNSPSC
12352005
Target
GSK-3; Wnt; β-catenin
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/laduviglusib-dihydrochloride.html
Solubility
10 mM in DMSO
Smiles
N#CC1=CC=C(N=C1)NCCNC2=NC=C(C(C3=CC=C(Cl)C=C3Cl)=N2)C4=NC=C(N4)C.[H]Cl.[H]Cl
Molecular Formula
C22H20Cl4N8
Molecular Weight
538.26
References & Citations
[1]Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52 (3) :588-95.|[2]Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7 (4) :e35892.|[3]Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog